How do biosimilars sustain value, affordability, and access to oncology care?

Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):327-329. doi: 10.1080/14737167.2020.1813570. Epub 2020 Sep 8.

Author

Steven Simoens¹

Affiliation

¹ Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

PMID: 32842809
DOI: 10.1080/14737167.2020.1813570

No abstract available

Keywords: Biosimilar; access; budget impact; oncology; value.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / economics*
Biosimilar Pharmaceuticals / administration & dosage
Biosimilar Pharmaceuticals / economics*
Costs and Cost Analysis
Drug Costs
Health Services Accessibility
Humans
Neoplasms / drug therapy*
Neoplasms / economics

Substances

Antineoplastic Agents
Biosimilar Pharmaceuticals